View Financial HealthAbera Bioscience 配当と自社株買い配当金 基準チェック /06Abera Bioscience配当金を支払った記録がありません。主要情報n/a配当利回り-23.3%バイバック利回り総株主利回り-23.3%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesBoard Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Harry Rastedt was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 13Abera Bioscience AB to Report Q1, 2026 Results on May 12, 2026Abera Bioscience AB announced that they will report Q1, 2026 results on May 12, 2026お知らせ • Jan 13Abera Bioscience AB to Report Fiscal Year 2025 Results on Feb 12, 2026Abera Bioscience AB announced that they will report fiscal year 2025 results on Feb 12, 2026お知らせ • Oct 15Abera Bioscience AB to Report Q3, 2025 Results on Nov 13, 2025Abera Bioscience AB announced that they will report Q3, 2025 results on Nov 13, 2025お知らせ • Jul 23Abera Bioscience AB to Report Q2, 2025 Results on Aug 21, 2025Abera Bioscience AB announced that they will report Q2, 2025 results on Aug 21, 2025お知らせ • Apr 14Abera Bioscience AB to Report Q1, 2025 Results on May 13, 2025Abera Bioscience AB announced that they will report Q1, 2025 results on May 13, 2025お知らせ • Apr 10Orexo Announces Positive In-Vivo Proof-Of-Concept Data for Powder-Based Intranasal Vaccine Formulated with the Amorphox TechnologyOrexo AB (publ.) announced positive in-vivo proof-of-concept data for a powder-based intranasal vaccine candidate formulated with the AmorphOX technology. The data was generated under the collaboration between Orexo and Abera Biosciences ("Abera") entered in December 2024. The proof-of-concept study was conducted in rats where Abera's influenza vaccine candidate was administered intranasally, either formulated as a liquid nasal solution or as an intranasal powder using Orexo's AmorphOX technology. Both formulations induced strong systemic antibody response in serum (IgG) as well as locally in the nose and lungs (IgA). No difference in immune response was seen between the liquid nasal solution and the intranasal powder. An intranasal influenza vaccine has the potential to easily and effectively help reduce the spread of infections and prevent disease, which could play an important role in a potential future pandemic. Formulating vaccines in powder form using the AmorphOX technology provides the potential to develop cost-efficient, thermostable vaccines with no need for cold chain requirements.お知らせ • Jan 15Abera Bioscience AB to Report Fiscal Year 2024 Results on Feb 13, 2025Abera Bioscience AB announced that they will report fiscal year 2024 results on Feb 13, 2025お知らせ • Oct 15Abera Bioscience AB to Report Q3, 2024 Results on Nov 13, 2024Abera Bioscience AB announced that they will report Q3, 2024 results on Nov 13, 2024お知らせ • Jul 23Abera Bioscience AB to Report Q2, 2024 Results on Aug 21, 2024Abera Bioscience AB announced that they will report Q2, 2024 results on Aug 21, 2024お知らせ • Apr 16Abera Bioscience AB to Report Q1, 2024 Results on May 14, 2024Abera Bioscience AB announced that they will report Q1, 2024 results on May 14, 2024お知らせ • Jan 24Abera Bioscience AB to Report Fiscal Year 2023 Results on Feb 22, 2024Abera Bioscience AB announced that they will report fiscal year 2023 results on Feb 22, 2024お知らせ • Oct 16Abera Bioscience AB to Report Q3, 2023 Results on Nov 14, 2023Abera Bioscience AB announced that they will report Q3, 2023 results on Nov 14, 2023Board Change • Sep 20No independent directorsThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 6 new directors. 2 experienced directors. 1 highly experienced director. No independent directors (4 non-independent directors). Executive Chairman of Board Anders Ericsson is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • Aug 21No independent directorsThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 6 new directors. 2 experienced directors. 1 highly experienced director. No independent directors (4 non-independent directors). Executive Chairman of Board Anders Ericsson is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Jul 18Abera Bioscience AB to Report Q2, 2023 Results on Aug 16, 2023Abera Bioscience AB announced that they will report Q2, 2023 results on Aug 16, 2023Board Change • Feb 23No independent directorsThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 7 new directors. 2 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Executive Chairman of Board Anders Ericsson is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • Feb 02No independent directorsThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 7 new directors. 2 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Executive Chairman of Board Anders Ericsson is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Jan 25Abera Bioscience AB to Report Fiscal Year 2022 Results on Feb 23, 2023Abera Bioscience AB announced that they will report fiscal year 2022 results on Feb 23, 2023Board Change • Nov 21No independent directorsThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 6 new directors. 3 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Executive Chairman of Board Anders Ericsson is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • May 17Abera Bioscience AB, Annual General Meeting, Jun 14, 2022Abera Bioscience AB, Annual General Meeting, Jun 14, 2022.Board Change • Apr 28No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Member of the Advisory Board Camille Locht was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Feb 24No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Member of the Advisory Board Camille Locht was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.決済の安定と成長配当データの取得安定した配当: 8WKの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: 8WKの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Abera Bioscience 配当利回り対市場8WK 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (8WK)n/a市場下位25% (DE)1.5%市場トップ25% (DE)4.5%業界平均 (Biotechs)2.2%アナリスト予想 (8WK) (最長3年)n/a注目すべき配当: 8WKは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: 8WKは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: 8WKの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: 8WKが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YDE 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 04:23終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Abera Bioscience AB 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Niklas ElmhammerCarlsquare ABHerman KuntscherCarlsquare AB
Board Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Harry Rastedt was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 13Abera Bioscience AB to Report Q1, 2026 Results on May 12, 2026Abera Bioscience AB announced that they will report Q1, 2026 results on May 12, 2026
お知らせ • Jan 13Abera Bioscience AB to Report Fiscal Year 2025 Results on Feb 12, 2026Abera Bioscience AB announced that they will report fiscal year 2025 results on Feb 12, 2026
お知らせ • Oct 15Abera Bioscience AB to Report Q3, 2025 Results on Nov 13, 2025Abera Bioscience AB announced that they will report Q3, 2025 results on Nov 13, 2025
お知らせ • Jul 23Abera Bioscience AB to Report Q2, 2025 Results on Aug 21, 2025Abera Bioscience AB announced that they will report Q2, 2025 results on Aug 21, 2025
お知らせ • Apr 14Abera Bioscience AB to Report Q1, 2025 Results on May 13, 2025Abera Bioscience AB announced that they will report Q1, 2025 results on May 13, 2025
お知らせ • Apr 10Orexo Announces Positive In-Vivo Proof-Of-Concept Data for Powder-Based Intranasal Vaccine Formulated with the Amorphox TechnologyOrexo AB (publ.) announced positive in-vivo proof-of-concept data for a powder-based intranasal vaccine candidate formulated with the AmorphOX technology. The data was generated under the collaboration between Orexo and Abera Biosciences ("Abera") entered in December 2024. The proof-of-concept study was conducted in rats where Abera's influenza vaccine candidate was administered intranasally, either formulated as a liquid nasal solution or as an intranasal powder using Orexo's AmorphOX technology. Both formulations induced strong systemic antibody response in serum (IgG) as well as locally in the nose and lungs (IgA). No difference in immune response was seen between the liquid nasal solution and the intranasal powder. An intranasal influenza vaccine has the potential to easily and effectively help reduce the spread of infections and prevent disease, which could play an important role in a potential future pandemic. Formulating vaccines in powder form using the AmorphOX technology provides the potential to develop cost-efficient, thermostable vaccines with no need for cold chain requirements.
お知らせ • Jan 15Abera Bioscience AB to Report Fiscal Year 2024 Results on Feb 13, 2025Abera Bioscience AB announced that they will report fiscal year 2024 results on Feb 13, 2025
お知らせ • Oct 15Abera Bioscience AB to Report Q3, 2024 Results on Nov 13, 2024Abera Bioscience AB announced that they will report Q3, 2024 results on Nov 13, 2024
お知らせ • Jul 23Abera Bioscience AB to Report Q2, 2024 Results on Aug 21, 2024Abera Bioscience AB announced that they will report Q2, 2024 results on Aug 21, 2024
お知らせ • Apr 16Abera Bioscience AB to Report Q1, 2024 Results on May 14, 2024Abera Bioscience AB announced that they will report Q1, 2024 results on May 14, 2024
お知らせ • Jan 24Abera Bioscience AB to Report Fiscal Year 2023 Results on Feb 22, 2024Abera Bioscience AB announced that they will report fiscal year 2023 results on Feb 22, 2024
お知らせ • Oct 16Abera Bioscience AB to Report Q3, 2023 Results on Nov 14, 2023Abera Bioscience AB announced that they will report Q3, 2023 results on Nov 14, 2023
Board Change • Sep 20No independent directorsThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 6 new directors. 2 experienced directors. 1 highly experienced director. No independent directors (4 non-independent directors). Executive Chairman of Board Anders Ericsson is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • Aug 21No independent directorsThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 6 new directors. 2 experienced directors. 1 highly experienced director. No independent directors (4 non-independent directors). Executive Chairman of Board Anders Ericsson is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Jul 18Abera Bioscience AB to Report Q2, 2023 Results on Aug 16, 2023Abera Bioscience AB announced that they will report Q2, 2023 results on Aug 16, 2023
Board Change • Feb 23No independent directorsThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 7 new directors. 2 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Executive Chairman of Board Anders Ericsson is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • Feb 02No independent directorsThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 7 new directors. 2 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Executive Chairman of Board Anders Ericsson is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Jan 25Abera Bioscience AB to Report Fiscal Year 2022 Results on Feb 23, 2023Abera Bioscience AB announced that they will report fiscal year 2022 results on Feb 23, 2023
Board Change • Nov 21No independent directorsThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 6 new directors. 3 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Executive Chairman of Board Anders Ericsson is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • May 17Abera Bioscience AB, Annual General Meeting, Jun 14, 2022Abera Bioscience AB, Annual General Meeting, Jun 14, 2022.
Board Change • Apr 28No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Member of the Advisory Board Camille Locht was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Feb 24No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Member of the Advisory Board Camille Locht was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.